文献速递消化道肿瘤放疗放疗物理与技术

抑制细胞周期蛋白依赖性激酶1增强胰腺癌放射敏感性

Enhanced radiosensitivity of pancreatic cancer achieved through inhibition of Cyclin-dependent kinase 1.
PubMed 文献 · Radiother Oncol · 2024-09-11

本研究通过基因和药物抑制CDK1探索胰腺导管腺癌(PDAC)放射增敏策略。磷酸化蛋白质组学显示放射抵抗克隆中磷酸化CDK1(Tyr15)显著升高,CDK1高表达与PDAC患者总生存期较差相关。在MIA PaCa-2和PANC-1细胞中,CDK1抑制与放疗协同延迟体内肿瘤生长,RO-3306预处理导致细胞G2/M期阻滞并破坏放疗后DNA修复,增强PDAC细胞放射敏感性。

要点

  • 放射抵抗PDAC细胞克隆中磷酸化CDK1(Tyr15)显著升高。
  • CDK1高表达与PDAC患者总生存期较差相关。
  • CDK1抑制联合放疗协同延迟MIA PaCa-2和PANC-1细胞体内肿瘤生长。

核心结论

  • CDK1在PDAC放射抵抗中起关键作用,靶向CDK1联合放疗在PDAC治疗中有待进一步研究。

研究设计与样本

  • 使用质谱和磷酸化蛋白质组学分析放射抵抗PDAC细胞系(MIA PaCa-2和PANC-1)与亲本对照。
  • 查询TCGA PDAC数据库,按CDK1 mRNA表达中位数将患者二分类分析临床结局。
  • 构建microRNA-based TET-on可诱导shRNA在两种PDAC细胞系中抑制CDK1表达。
  • 使用PDAC原位模型测试有无多西环素治疗时PDAC肿瘤的放射敏感性。
  • 使用选择性CDK1抑制剂RO-3306靶向CDK1激活,并进行免疫印迹、免疫细胞化学和克隆形成实验。

主要发现

  • 磷酸化蛋白质组学分析显示放射抵抗克隆中磷酸化CDK1(Tyr15)显著升高。
  • CDK1高表达与PDAC患者总生存期较差相关。
  • 辐射暴露增加CDK1磷酸化。
  • 在MIA PaCa-2和PANC-1细胞中,CDK1抑制与放疗协同延迟体内肿瘤生长。
  • RO-3306抑制CDK1导致细胞显著向G2/M期偏移,并破坏辐射暴露后的DNA修复;体外RO-3306预处理增强PDAC细胞放射敏感性。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND PURPOSE: Overcoming radioresistance is a critical challenge in pancreatic ductal adenocarcinoma (PDAC). Our study investigates the targeting of Cyclin-dependent kinase-1 (CDK1) through genetic and pharmaceutical inhibition to radiosensitize PDAC cells. MATERIALS AND METHODS: Mass spectrometry and phosphoproteomics were used to analyze engineered radiation-resistant PDAC cell lines (MIA PaCa-2 and PANC-1) compared to parental controls. The TCGA PDAC database was queried for clinical outcomes and patients were dichotomized based on the median CDK1 mRNA expression. We generated a microRNA-based TET-on inducible shRNA to inhibit CDK1 expression in two PDAC cell lines. We used an orthotopic model of PDAC to test the radiation sensitivity of PDAC tumors with or without doxycycline treatment. We targeted CDK1 activation with a selective CDK1 inhibitor, RO-3306, followed by in vitro experiments employing immunoblotting, immunocytochemistry, and clonogenic assays. RESULTS: Phosphoproteomics analysis revealed that phospho-CDK1 (Tyr15) was significantly elevated in the resistant clones. We found that high CDK1 expression was associated with worse OS in PDAC patients. Radiation exposure increased CDK1 phosphorylation. In MIA PaCa-2 and PANC-1 cells, CDK1 inhibition synergized with radiation therapy to delay tumor growth in vivo. CDK1 inhibition via. RO-3306 resulted in a significant shift of cells into the G2/M phase and disrupted DNA repair after radiation exposure. In vitro, pre-treatment with RO-3306 led to enhanced radiosensitivity of PDAC cells. CONCLUSION: CDK1 plays a crucial role in PDAC radioresistance. Targeting CDK1 with radiotherapy holds promise for further investigation in PDAC treatment.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Van Matre S, Huq S, Akana L, et al. Enhanced radiosensitivity of pancreatic cancer achieved through inhibition of Cyclin-dependent kinase 1. Radiother Oncol. 2024. PMID: 39270987. doi:10.1016/j.radonc.2024.110531

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。